Vascular Calcification Clinical Trial
— TReVasc-HDKOfficial title:
Treatment to Reduce Vascular Calcification in Hemodialysis Patients Using Vitamin K (Trevasc-HDK): A Study Protocol for a Randomized Controlled Trial
Verified date | January 2023 |
Source | National University Health System, Singapore |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The proposed study will seek to evaluate the prevalence and the progression of vascular calcification in a cohort of maintenance hemodialysis patients in Asian population. It will also evaluate the efficacy of vitamin K 2 supplementation in reducing the progression of vascular calcification in this group of patients. This will be a single-center randomized, prospective and open-label interventional clinical trial of end stage renal failure patients on hemodialysis.Primary outcome will be absolute difference in coronary artery calcium (CAC) score at 18-month between control and intervention arms. Secondary outcomes will be to compare absolute difference in aortic valve calcification, percentage of patients with regression of coronary artery calcification of at least 10%, absolute difference in aortic and systemic arterial stiffness, mortality from any cause and major adverse cardiovascular events (MACE) over the same period.
Status | Completed |
Enrollment | 178 |
Est. completion date | February 2022 |
Est. primary completion date | February 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Age = 45 years and less than 80 years 2. At least 12 months on Hemodialysis 3. Coronary artery calcium score of = 30 in the baseline Multislice Computed Tomography 4. Able to give informed consent 5. Life expectancy of at least18 months Exclusion Criteria: 1. History of thrombosis in the last 6 months except vascular access thrombosis 2. Need for vitamin K antagonists therapy at baseline or in the 3 months prior to baseline 3. Presence of significant gut disease (inflammatory bowel disease, short-bowel syndrome) 4. Liver dysfunction 5. Alcohol or drug abuse 6. Presence of coronary stent or have undergone coronary artery bypass grafting 7. Women who are pregnant or breast feeding, 8. Those who are fearful of confined space and cannot lie still for Multislice Computed Tomography 9. Lack of safe contraceptive measures. 10. Those who had parathyroid surgery done. 11. Those with parathyroid hormone (PTH) > 150 pmol/l 12. Patient taking multivitamins containing vitamin K 13. Patient allergic to soy based products |
Country | Name | City | State |
---|---|---|---|
Singapore | National University Hospital | Singapore |
Lead Sponsor | Collaborator |
---|---|
National University Health System, Singapore | National Medical Research Council (NMRC), Singapore, Nattopharma ASA |
Singapore,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Absolute difference in coronary artery calcium score at 18-month between control and intervention arms | Comparison made using the t-test following log transformation. Adjustment for baseline CAC scores made via the analysis of covariance. | 18 months | |
Secondary | Absolute difference in AVC score at 18-months | Comparison made using the t-test following log transformation. Adjustment for baseline AVC scores made via the analysis of covariance. | 18 months | |
Secondary | Percentage of patients with regression of CAC of = 10% over 18-month | 18 months | ||
Secondary | Absolute difference in cfPWV and AI at 18-months | 18 months | ||
Secondary | Mortality from any cause within the study period | 18 months | ||
Secondary | MACE defined as non-fatal myocardial infarction, heart failure, acute coronary syndrome, need for coronary revascularization, non-fatal stroke, significant peripheral vascular disease | 18 months | ||
Secondary | Difference in plasma levels of dp-ucMGP at 18 months | 18 months | ||
Secondary | Vascular access events, including clotting requiring insertion of a new dialysis catheter, declotting or exchange of an existing catheter, and vascular intervention during the study period | 18 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03960437 -
The Effect of Etelcalcetide on CKD-MBD
|
Phase 2 | |
Recruiting |
NCT04983875 -
Mammography and Breast Arterial Calcification: An Information-Sharing Trial
|
N/A | |
Completed |
NCT03292029 -
Pilot Medical Evaluation of the T50 Test
|
N/A | |
Completed |
NCT02561299 -
Orbital Vessel PreparaTIon to MaximIZe Dcb Efficacy in Calcified Below the Knee (BTK) Lesions - A Pilot Study
|
N/A | |
Completed |
NCT00379899 -
ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
|
Phase 4 | |
Active, not recruiting |
NCT02598635 -
Effects of Cholecalciferol on Osteoprotegerin Levels in Patients on Peritoneal Dialysis
|
Phase 4 | |
Completed |
NCT00183001 -
Effect of Vitamin K on Age-Related Bone Loss and Vascular Calcification
|
Phase 3 | |
Completed |
NCT04114695 -
Aortic Calcification and Central Blood Pressure in Patients With Chronic Kidney Disease
|
||
Not yet recruiting |
NCT03169400 -
Theranova Dialyzer and Chronic Kidney Disease - Mineral Bone Disorder (CKD-MBD)
|
N/A | |
Completed |
NCT03314493 -
Prevention of the Progression of Coronary Calcification With Use of Spironolactone in Peritoneal Dialysis Patients
|
Phase 3 | |
Completed |
NCT03839732 -
Observer Variability in Scoring Abdominal Aortic Calcifications and Vertebral Morphometry
|
||
Completed |
NCT02542319 -
Effect of Oral Magnesium on Vascular Calcification in Chronic Kidney Disease
|
Phase 2 | |
Completed |
NCT02610933 -
Effect on Vascular Calcification of Replacing Warfarin by Rivaroxaban With or Without VitK2 in Hemodialysis Patients
|
Phase 4 | |
Completed |
NCT00481364 -
Atorvastatin Treatment to Attenuate the Progression of Cardiovascular Disease in Hemodialysis Patients
|
Phase 3 | |
Completed |
NCT00694824 -
Vascular Calcification's Risk Factors in Haemodialysis Patients
|
||
Recruiting |
NCT01364688 -
Oral Alfacalcidol and Coronary Artery Calcification in Predialysis Chronic Kidney Disease
|
Phase 2 | |
Completed |
NCT01675206 -
Dose Defining Study for the Administration of Vitamin K2 Supplements in Hemodialysis Patients
|
Phase 3 | |
Completed |
NCT03937349 -
Impact of Parathyroidectomy on Cardiovascular Calcification in Dialysis-dependent Patients
|
||
Completed |
NCT02719665 -
THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease
|
N/A | |
Recruiting |
NCT04753593 -
Use of Discarded Surgery Human Tissue Specimens for Basic Science Research
|